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 ABSTRACT 
Previous studies in several fish species have shown efficacy of a low-dose garlic 
compound, allicin, against several pathogens. In this study, young rainbow trout (Oncorhynchus 
mykiss) were fed diets containing 0%, 0.5%, 1.0% and 2.0% allicin and then challenged with a 
modified LD50 dose of Aeromonas salmonicida and monitored for 28 days.  There were 
significant increases in survivability in the 0.5% and 1.0% groups and a significant reduction in 
survival at the 2.0% dose.  A target animal safety was performed using the target dose of 0.5% 
allicin at 0x, 1x, 3x, and 5x the target dose for 3x the duration (6 weeks) of the original study.  
There were no statistically significant differences in erythrocyte parameters or average leukocyte 
counts; however, there was a significant decrease in the level of circulating monocytes in the 
high dose (2.5%) group.   This correlated to an increased level of pigment-containing 
macrophage centers within the renal tissue as allicin dosing increased, denoting a potential 
inflammatory effect.  On serum chemistry, glutamate dehydrogenase (GDH) was elevated, most 
likely as a result of increased cellular metabolism and increased hepatocyte turnover due to 
allicin dosing.  Initial studies indicate that feeding 0.5% allicin improves survivability when 
challenged with A. salmonicida and appears safe; however, higher levels may cause negative 
effects on health.  
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CHAPTER ONE: 
INTRODUCTION 
Overview 
Aquaculture is an important economic asset for many countries, with an estimated $1 
billion annual production in the United States alone and over $100 billion of production 
worldwide.  Although the U.S. is a relatively small producer of aquaculture products, it is one of 
the largest seafood importers worldwide, with a trade deficit of over $10.4 billion annually 
(NOAA 2013).  As aquaculture grows, it is important to emphasize aquatic animal welfare as it 
has broad impacts on stress response and resistance to disease, which in turn has serious 
consequences on industry sustainability (Ashley 2007).  
Due to high product demand, high operating costs, and limited environmental resources, 
aquaculture facilities often hold a large number of animals within a small space, resulting in the 
need for emphasis on improved health management to reduce stress and associated 
morbidity/mortality. Stressors within the aquaculture setting include physical stressors 
(temperature fluctuations, water quality changes, sounds, lights, and dissolved gasses), biological 
stressors (high density, spawning season, pathogenic and nonpathogenic microorganisms, and 
internal and external parasites), chemical stressors (poor water quality, pollution, improper diet 
composition, and metabolic waste products) and procedural stressors (disease treatments, 
handling, and shipping).  All of these factors have the ability to influence the health of the 
animals as well as their susceptibility to disease, which is why it is essential to ensure 
appropriate animal welfare and health management (Francis-Floyd 2012). 
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It is well known that diet has a strong effect on health and stress tolerance; therefore, it is 
essential to feed adequate quantities of diets meeting all nutritional requirements for proper 
growth and health (Trichet 2010).  Information on required nutrients in aquatic species is limited, 
though basic data is available to assure minimum requirements are met in diet formulations for 
the majority of common species; however, data concerning bioavailability and metabolism of 
these nutrients is often lacking (Oliva-Teles 2012).  Dietary factors, including essential and non-
essential nutrients, have been shown to have specific effects on the immune response when 
provided at pharmacological levels (Trichet 2010).  Additionally, constituents other than 
essential nutrients, such as probiotics, prebiotics, and immunostimulants, have been considered 
in aquatic nutrition to improve feed efficiency/growth, health, stress tolerance, and resistance to 
disease (Oliva-Teles 2012).  
While it is generally possible for disease management to be accomplished using 
pharmaceutical drugs, this method has a high consequence in terms of environmental 
contamination and drug resistance.  Additionally, aquaculture animals are meant for human 
consumption; therefore, only FDA-labeled drugs can be used and withdrawal periods must be 
specified and closely observed. 
Currently in the United States, there are only three FDA-labeled antibiotics for usage in 
aquaculture. These drugs are florfenicol (Aquaflor®), oxytetracycline (Terramycin®-200 for 
Fish), and sulfadimethoxine/ormetoprim (Romet®-30), which are labeled for specific culture-
positive pathogens within specific aquatic species (FDA 2013).  There is a large concern that the 
usage of antibiotics within aquatic systems will have significant impacts on the environment, 
ecosystem, and other species. Historically, antibiotic overuse in aquaculture, agriculture, and 
human medicine have allowed for the development of multi-drug resistant bacteria, resistance 
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genes, and drug residues found within the environment.  Since antibiotic resistance is a major 
concern, prevention measures, including risk management, environmental management, and 
alternative treatment measures, including vaccination, have become much more predominant in 
aquaculture, with antibiotic usage recommended as a last resort (FAO/WHO/OIE 2006).   
Dietary Supplementation and Allicin 
In an attempt to find alternative methods to pharmaceutical drugs for the prevention and 
treatment of disease in aquatic organisms, dietary supplements have been suggested for use in 
aquaculture.  In order for a dietary supplement to be used, it must be effective, low-cost, and 
palatable to the fish.   
The usage of therapeutic or medicinal dietary supplements (e.g. plants, minerals, oils) in 
humans has been practiced for thousands of years in many cultures.  Ancient civilizations, 
including Egyptian, Greek, Indian, Roman, Viking, and Chinese, utilized garlic for the treatment 
of varied health conditions as early as 3,000 B.C. (Block 1985; Rivlin 2001).  Garlic is a proven 
prophylactic and therapeutic in humans and agricultural species, leading to interest in its use in 
aquaculture.  It is easily obtained, inexpensive, and acts against a broad spectrum of pathogens.  
The efficacy depends on the formulation, dose, and route of administration and overdosing may 
have negative impacts; therefore, it is important to optimize the dosing for each species prior to 
usage (Lee and Gao 2012). 
Garlic (Allium sativum) belongs to the Liliaceae family and is cultivated across the world 
for its fleshy bulbs (cloves).  The main biological effects of garlic are attributed to its 
characteristic organosulfur compounds.  The principle active substance in garlic is allicin (diallyl 
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thiosulfate), which is responsible for its pungent smell and its therapeutic properties.  Allicin is 
activated by crushing or cutting the garlic cloves (Block 1985).  
Garlic has a wide spectrum of activity, including antibacterial (Cavallito and Bailey 
1944), antiviral (Weber, Andersen et al. 1992), antiprotozoal (Ankri, Miron et al. 1997), and 
antifungal (Gupta and Porter 2001).  In terms of antibacterial properties, garlic has effects on 
both gram-negative and gram-positive bacteria as well as effects on many drug resistant strains 
of bacteria, such as methicillin-resistant Staphylococcus aureus (Cutler and Wilson 2004) and 
Helicobacter pylori (Jonkers, van den Broek et al. 1999). 
Though the exact mechanisms of allicin are not fully understood, it is generally accepted 
that allicin facilitates the function of phagocytic cells and increases their bactericidal activities; 
additionally, it stimulates natural killer cells, complement, lysozyme, and antibody responses 
(Talpur and Ikhwanuddin 2012).  The up-regulation of these immunological functions are 
associated with increased protection against infectious disease (Lee and Gao 2012).  Allicin can 
also function directly on pathogens, by completely inhibiting RNA synthesis as well as partially 
inhibiting DNA and protein synthesis (Feldberg, Chang et al. 1988).  Functional activities of 
garlic include free radical scavenging activities, immune up regulation, anti-infectious and anti-
cancer properties, and cardiovascular disease treatment (Colic and Savic 2000; Harris, Cottrell et 
al. 2001; Khanum, Anilakumar et al. 2004; Borek 2006; Herman-Antosiewicz, Powolny et al. 
2007; Singh, Vinjamury et al. 2007). 
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Figure 1: Summary of the therapeutic effects of allicin (Chan, Yuen et al. 2013) 
Herbs initially add flavor to foods and thereby influence eating patterns, the secretion of 
digestive fluids, and total feed intake (Lee and Gao 2012).  Allicin has a strong stimulatory effect 
on olfaction in many aquatic animals, inducing fish to eat and subsequently increasing feed 
intake.  Additionally, allicin can enhance immune-competence, improve gastric motility, and 
modulate secretion of enzymes to improve digestion and nutrient absorption (Lee and Gao 2012). 
Several studies have documented the effect of allicin as a growth promoter in multiple species, 
including carp and tilapia, after long-term dosing of at least three months (Fo, Han et al. 1990; 
Zeng, Ren et al. 1996; Jia, Hu et al. 1997; Hu 1999; Jia 1999).   
However, results of several other studies have demonstrated that garlic is not optimal for 
all fish species and can be very dose-dependent.  Hatching rates of Manila clam (Ruditapes 
philippinarum) decreased with increasing concentrations of allicin (Yang, Zuo et al. 2010), 
growth rates declined in the red belly pacu (Colossoma barchypomum) with increasing 
concentrations of allicin (Xiang and Liu 2002), and the rice field eel (Monopterus albus) died 
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after being fed allicin.  (Huang, He et al. 2001).  This again highlights the fact that while garlic 
has many health benefits, it is important to optimize the dosing prior to usage in any species. 
Several recent studies have demonstrated the ability of dietary supplements, including 
garlic, to upregulate immunity and increase resistance to disease in multiple fish species.   One 
study determined that diets supplemented with dried rosemary (Rosmarinus officinalis) 
significantly reduced mortality in tilapia (Oreochromis spp) infected with Streptococcus 
agalactiae (Zilberg, Tal et al. 2010). Another study determined that Nile tilapia (Oreochromis 
niloticus) fed either Echinacea (Ecinacea purpurea) or garlic showed significant disease 
resistance when challenged with Aeromonas hydrophila as well as a significant increase in 
survival rate, leucocyte count, and body weight (Aly and Mohamed 2010). In Asian sea bass 
(Lates calcirifer) challenged with Vibrio harveyi infection, garlic supplementation at 10g/kg feed 
significantly improved survival. Additionally, there was a significant increase in growth, weight 
gain, and feed conversion in garlic fed groups as well as enhanced erythrocytes, leucocytes, 
hematocrit, hemoglobin, phagocytic activity, respiratory burst, lysozyme, anti-protease, and 
bactericidal activities (Talpur and Ikhwanuddin 2012). 
This thesis expands upon studies performed by Drs. Nya and Austin, in which rainbow 
trout (Oncorynchus mykiss) were fed allicin at varied concentrations (0%, 0.5%, and 1%), 
challenged with the bacteria Aeromonas hydrophila, and monitored for morbidity and mortality.  
Mortality was reduced from 80% in the controls to 8% (0.5% dose) and 0% (1.0% dose).  The 
Nya and Austin studies concluded that allicin was highly inhibitory against A. hydrophila and did 
not affect body weight, length, or weight gain.  Additionally, fish fed allicin had higher quantity 
of erythrocytes and lymphocytes, with increased serum protein, serum lysosome activity, and 
serum bactericidal activity (Nya and Austin 2009; Nya, Dawood et al. 2010; Nya and Austin 
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2011).  Though allicin is generally an unstable compound, this study also found that an allicin 
supplemented diet provided protection against A. hydrophila up to 28 days, though there was a 
steady reduction in the level of protection as time passed (Nya and Austin 2011).  Our study 
followed the materials and methods from the Nya and Austin 2009 study, including feed 
preparation and feed duration, but a different common salmonid pathogen, Aeromonas 
salmonicida, was used for the infection challenge. 
In work performed by our collaborator, Dr. George Ketola, multiple essential oils were 
used in-vitro to determine minimum inhibitory concentration against A. salmonicida.  Dr. Ketola 
determined that allicin was inhibitive against growth of A. salmonicida on culture at 10% and 
20% emulsions, demonstrating that allicin has direct effects on bacterial metabolism (Ketola, 
Starliper et al. 2012).  
Aeromonas salmonicida 
Furunculosis, a disease caused by Aeromonas salmonicida, can have significant 
economic impacts on fish, especially in the intensive aquaculture setting.  Typically this 
bacterium affects salmonids, though atypical strains can infect many warm water, cold water, 
freshwater, and marine species (Bullock, Cipriano et al. 1983).  
A. salmonicida is a gram-negative, non-motile rod, which grows readily on tryptic soy 
agar or brain-heart infusion agar and forms a brown diffusible pigment, usually within 72 hours 
at room temperature. Virulence factors include the production of extracellular products, such as 
hemolysins, proteases, and leucocidin, which are associated with the majority of the pathology 
associated with clinical signs (Cipriano 1983).  Additionally, it was discovered that virulent 
strains have an extra-membrane protein called the “A-layer,” which enhances bacterial cell 
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hydrophobicity, cell-to-cell aggregation, and cell-to-tissue adhesion (Udey and Fryer 1978). One 
method to determine whether a strain is virulent is culture on Coomassie Brilliant Blue agar 
(CBB) (Markwardt, Gocha et al. 1989). CBB is a protein specific dye, incorporated into common 
growth media, which can differentiate between A-layer positive and A-layer negative strains.  
For A-layer positive strains, the dye is incorporated into the colony growth, presenting as blue 
colonies, whereas A-layer negative strains do not incorporate the dye and will present as white 
colonies (Cipriano and Bertolini 1988). 
Transmission occurs through contact with infected fish and contaminated water.  
Individuals that survive epizootic disease usually become carriers and serve as the prime 
reservoir for infection (Cipriano 1983).  Although A. salmonicida typically does not survive in 
environments without fish, some mutated strains are able to survive in bodies of water, on 
equipment, and in tissues from dead fish for 6-32 days (McCarthy 1977).  
In peracute infections, fingerlings turn dark in color and die. Clinical signs are generally 
not observed with the exception of slight exophthalmos.  Acute infections occur in sub-adult and 
adult fish, with signs of darkened coloration, anorexia, and hemorrhage at the base of the fins. 
Internal hemorrhage also occurs within the viscera, abdominal walls, and heart. Other gross 
findings include splenomegaly, petechial hemorrhage, and sloughed epithelium, mucus, and 
blood within the gastrointestinal tract.  In chronic furunculosis, usually in older fish, “furuncles” 
may be present on the flanks as well as visceral congestion and peritonitis.  Furuncles in fish are 
described as areas of necrotic tissue, fluid exudate, and macrophages, differing from true 
furuncles of homeotherms (Klontz, Yasutake et al. 1966; McCarthy and Roberts 1980; Ellis, 
Hastings et al. 1981; Bullock, Cipriano et al. 1983).  
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In experimentally infected fish injected intramuscularly, a focus of infection develops at 
the site of injection, resulting in myofibrillar necrosis, vascular necrosis, and hemorrhage.  
Severe leukopenia occurs within 72 hours with resulting septicemia.  In natural infections, foci of 
bacteria within minimal to no inflammation occur in the kidneys, spleen and myocardium, 
leading to hematopoietic necrosis and myocardial and renal tubular degeneration.  In chronically 
infected fish, heart and spleen are the most commonly affected organs (Klontz, Yasutake et al. 
1966; McCarthy and Roberts 1980; Ellis, Hastings et al. 1981; Bullock, Cipriano et al. 1983). 
Study Goals 
The goal of this study was to determine the efficacy and safety of allicin, when added to 
the diets of rainbow trout, as a management tool to reduce or eliminate the risk posed by the 
bacterial pathogen Aeromonas salmonicida. The study was based on the aforementioned in-vitro 
work by Ketola, 2012 as well as in-vivo work by Nya and Austin, 2011.  
Experimental Plan 
The work represented within this thesis was performed as three separate experiments.  
First, a direct infection trial was performed to determine the efficacy of allicin in animals 
infected intraceolomically with a modified LD50 (mLD50) dose of A. salmonicida.  Second, a 
target animal safety trial was performed to assess the safety of the compound at varied 
incremental doses based on the anticipated optimal dose. According to FDA guidelines, “the aim 
of target animal safety studies is to provide information on the safety of an investigational 
veterinary pharmaceutical product in the intended species under the proposed conditions of use.  
Furthermore, adverse effects associated with overdoses and increased duration of administration 
of the product should be identified” (FDA 2009).  Although allicin is a dietary supplement and 
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not a pharmaceutical product, the target animal safety trial was performed to assess safety using 
the same standards as a pharmaceutical product. Third, a waterborne infection trial was 
attempted in order to mimic a more natural route of infection with A. salmonicida to determine if 
fish fed allicin would be more resistant to bacterial contaminated water and infected fish.  
Hypotheses 
For the infection trials, the null hypothesis was that rainbow trout fed allicin at varying 
concentrations will not have improved survivability when challenged with A. salmonicida as 
compared to rainbow trout fed standard trout feed.  Additionally, there will be no difference in 
systemic quantities of bacteria based on the concentration of allicin fed.  There were three 
alternate hypotheses: 1) Rainbow trout fed allicin will have increased survivability when 
challenged with A. salmonicida as compared to rainbow trout fed standard trout feed; 2) 
Rainbow trout fed the highest dose (2% allicin) will have the best survivability when challenged 
with A. salmonicida; and 3) Rainbow trout fed allicin will have lower quantities of systemic A. 
salmonicida post-infection. 
 For the target animal safety trial, the null hypothesis was that rainbow trout fed allicin at 
0x (0%), 1x (0.5%), 3x (1.5%), and 5x (2.5%) the target concentration (0.5%) for 3x duration (6 
weeks) of the previous studies will not have effects on growth, erythrocyte and leukocyte panels, 
serum chemistry parameters, or gills, liver, kidney, and spleen (i.e., the compound is safe at all 
test doses).  The alternate hypothesis was that there is an effect on growth, erythrocyte and 
leukocyte panels, serum chemistry parameters, or gills, liver, kidney, and spleen based on the 
allicin dosing (i.e., the compound is detrimental/toxic at some doses). 
  
11 
CHAPTER TWO: 
MATERIALS AND METHODS 
 
Animal Husbandry 
All protocols were approved by the Cornell University Institutional Animal Care and Use 
Committee and the Tunison Laboratory of Aquatic Science, United States Geological Survey 
(USGS).   
For all infection studies, young rainbow trout (Oncorhynchus mykiss), approximately 4-
6cm total length (TL), were obtained from the USGS Tunison Laboratory of Aquatic Science 
(Cortland, NY) and the NYSDEC Bath Fish Hatchery (Bath, NY).  Fish were maintained in the 
Aquatic Animal Health Program Research Facility, College of Veterinary Medicine, Cornell 
University, a facility accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care International. The experimental holding system consisted of multiple 
75.7L glass aquaria placed in 719.2L Min-O-Cool (Frigid Units Inc., Toledo, OH) tanks 
individually supplied with de-chlorinated flowing water (15°C) and aeration.  Each larger tank 
held up to five 75.7L aquaria, with 14-20 fish per aquaria. 
For the target animal safety study, yearling rainbow trout, approximately 8-12cm TL, 
were maintained by the USGS Tunison Laboratory of Aquatic Science in outdoor concrete 
raceways (dimensions 1.5 x 5.8 x 0.5m; flow rate 5-7L/min) with water sourced from a local 
spring at ambient temperature.  This facility is managed in accordance with the American 
Fisheries Society Fish Health Section Blue Book (AFS 2012).  
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Establishment of a modified LD50 dose of Aeromonas salmonicida 
The modified LD50 dose of A. salmonicida was determined in five groups of fish.  Each 
group contained ten yearling rainbow trout (approximately 6cm TL).  All fish were injected with 
a 0.1mL intraceolomic (IC) injection containing either sterile saline or A. salmonicida at 10
3
 
CFU/0.1mL, 10
4
 CFU/0.1mL, 10
5
 CFU/0.1mL, or 10
6
 CFU/0.1mL.  Fish were held for 28 days 
and were monitored twice daily for morbidity or mortality.  Any fish exhibiting abnormal 
behavior or signs of illness/distress were euthanized immediately with an overdose of tricaine 
methanesulfonate (Tricaine-S, Western Chemical, Ferndale, WA) buffered with an equal weight 
of sodium bicarbonate (Sigma, St. Louis, MO).  Post mortem analysis included length and 
weight, a complete necropsy, and aseptic kidney culture on Brain Heart Infusion (BHI) agar 
(Becton Dickinson, Sparks, MD).   
Diet Preparation and Feeding 
A standard trout diet was used for the basis of all feed (Ziegler Feed – Slow Sinking 
2.5mm Finfish, Ziegler Bros., Inc., Gardener, PA).  Allicin as Allimed® liquid was obtained 
(Allicin International, East Sussex, TN) and feed was coated evenly depending on allicin 
treatment dosage: 0.5% (5mg Allimed®/1kg feed), 1.0% (10mg Allimed®/1kg feed) and 2.0% 
(20mg Allimed®/1kg feed). 
For fourteen days prior to infection, fish were fed test diets depending on group (control 
0%, 0.5% allicin, 1.0% allicin, 2.0% allicin) at 1% body weight per day.  Feed was withheld for 
one day post-infection.  For the remaining time on study, fish were fed control diet at 1% body 
weight per day (Nya and Austin 2011). 
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Feeding Trial by Direct Infection 
Study groups included uninfected negative controls, untreated infected positive controls 
(0% allicin dose), 0.5% allicin, 1.0% allicin, and 2.0% allicin.  Each treatment group contained 
20 fish, housed within 75.7L aquaria, with four replicate tanks per group (80 fish total per 
treatment).  Fish were randomized into study groups and tank assignments using a random 
number generator (random.org) and were fed their respective treatment diets for fourteen days 
prior to the beginning of the infection trial.  On day 0, all fish in the negative control group 
received a 0.1 mL IC injection of sterile 0.85 % saline and were housed in a specific pathogen 
free room (free of A. salmonicida).  All fish in the remaining study groups received a 0.1 mL IC 
injection containing a mLD50 dose of A. salmonicida (as determined by previous studies).  Fish 
were monitored twice daily for morbidity and mortality.  Any fish exhibiting abnormal behavior 
or signs of illness/distress were euthanized immediately with an overdose of tricaine 
methanesulfonate as previously described.  After 28 days, all fish were euthanized for analysis, 
including length and weight, complete necropsy, and aseptic kidney culture on BHI agar (Nya 
and Austin 2009; Nya, Dawood et al. 2010; Nya and Austin 2011).  Additionally, kidney tissue 
was collected for quantitative PCR (qPCR) to determine the quantity of A. salmonicida within 
each fish. 
Target Animal Safety Trial 
This study was performed in outdoor raceways at the Tunison Laboratory of Aquatic 
Science under USGS protocols.  The target dose was 0.5% allicin (as determined by previous 
infection studies).  Fish were fed test diets at 1% body weight per day containing 0% (0x),  1x 
0.5% (1x), 1.5% (3x), and 2.5% (5x) allicin for 6 weeks (3 times the length of the initial trials).  
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Each group contained between 23 and 27 fish.  At the termination of the study, all fish were 
euthanized with an overdose of tricaine methanesulfonate as previously described.  A blood 
sample was immediately collected from the ventral tail vein using a vacutainer collection system 
(Becton Dickinson) for a blood smear and clinical chemistry panel.  Gills, kidney, liver, and 
spleen were collected for histopathology.  
Feeding Trial by Waterborne Exposure 
Study groups included uninfected negative controls, untreated positive infected controls, 
0.5% allicin, 1.0% allicin, and 2.0% allicin.  Each group contained 14 fish, housed within 75.7L 
aquaria, with four replicate tanks per group (n=280).  Fish were randomized within study groups 
using a random number generator (random.org) and were fed their respective test diets for 
fourteen days prior to the beginning of the infection trial.  On day 0, four fish in the negative 
control group received a 0.1 mL IP injection of sterile saline and the remaining ten fish were not 
inoculated.  All negative control fish were housed in a specific pathogen free room (free of A. 
salmonicida).  For the remaining study groups, four fish per tank received a 0.1 mL IC injection 
containing a mLD50 dose of A. salmonicida (as determined by previous studies) and the 
remaining ten fish per tank were not inoculated.  Fish were monitored twice daily for morbidity 
and mortality.  Any fish exhibiting abnormal behavior or signs of illness/distress were euthanized 
immediately with an overdose of tricaine methanesulfonate as previously described.  After 38 
days, all fish were euthanized.  Analysis included length and weight, a complete necropsy, 
aseptic kidney culture on BHI agar, and quantitative PCR.  
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Blood Smear 
Blood smears were stained with Wrights stain by the New York State Animal Health 
Diagnostic Center (AHDC), Clinical Pathology (Ithaca, NY).  Erythrocytes were evaluated for 
morphology.  A leukocyte estimate was performed by counting the number of white blood cells 
per 10 high powered fields (HPF, 100X magnification), using the formula WBC estimate = 
Average # WBC/HPF x 3,500.  A leukocyte differential was performed by counting 100 white 
cells on 100x, noting the specific type of cell (lymphocyte, monocyte, and neutrophil) as a 
percentage of the total number observed. 
Serum Chemistry Panel 
Blood chemistry panels were performed by the AHDC, Clinical Pathology (Ithaca, NY).  
Approximately 1mL of serum per fish was submitted in a lithium heparinized tube (Becton 
Dickinson) for processing.   
Histopathology 
Tissues for histopathology were fixed in 10% neutral buffered formalin (Sigma, St. 
Louis, MO) for at least 24 hours.  Gills were further processed by placing them in 14% sodium 
EDTA (Sigma) for 7 days for decalcification (Luna 1968). All tissue cassettes were submitted to 
the AHDC Histology Laboratory for block preparation and slide processing with hematoxylin 
and eosin staining using using AHDC protocols. For density assessment of pigment-containing 
macrophage centers within the kidneys, a scoring system of 1-5 was created (1=no pigment-
containing macrophage centers to 5=heavy pigment-containing macrophage centers) and slides 
were scored by a blinded observer to determine trends. 
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Bacterial Preparation 
Aliquots of A. salmonicida strain 3.177 (obtained from a clinical salmonid case, courtesy 
Dr. Rocco Cipriano, USGS, Leetown, WV) were held at -80
o
C in 10% glycerol (Amresco, 
Solon, OH).  Prior to each study, an aliquot was thawed and plated onto BHI agar (Becton 
Dickinson) and allowed to grow at room temperature for 72 hours.  Additionally, an aliquot was 
plated onto Comassie Brilliant Blue (CBB) agar (Brilliant Blue R 250, Sigma-Aldrich) to 
confirm virulence as indicated by the presence of the A-layer.  After 72 hours of growth, 
approximately 20 colonies were suspended in BHI broth (Becton Dickinson).  The suspension 
was allowed to grow at room temperature with gentle agitation until reaching a 
spectrophotometer (Spectronic 21, Bausch and Lomb, Rochester, NY) reading of 0.06 OD525, 
which correlated to a 1x10
8
 CFU/mL reading according to previous growth curve studies 
performed within the laboratory with this strain of bacteria.  Serial 10-fold dilutions were 
performed with sterile saline to reach the pre-determined mLD50 dose.   
Bacterial Culture 
The posterior kidney was swabbed using aseptic technique and streaked onto BHI agar 
(Becton Dickinson).  Plates were held at room temperature for 7 to 21 days. Plates containing a 
brown-diffusible pigment were considered positive for A. salmonicida. 
DNA Extraction and Quantitative PCR 
A portion of posterior kidney was removed and placed in a sterile bead-beater tube 
(Biospec Products) containing a 1.3 mm chrome steel bead.   HMEM-10 (200 uL) was added to 
the samples and then the samples were homogenized using a Minibeater-16 (BioSpec Products) 
for 1 min.   Samples were then centrifuged at 8000 x g for 2 min prior to DNA 
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extraction.  Extraction of DNA was performed using a MagMax magnetic bead extraction system 
and the MagMax-96 viral RNA isolation kit (Life Technologies, Carlsbad, California) using the 
protocols described in the kit and the manufacturer-supplied extraction program 
AM1836_DW_50_V2.  Eluted DNA was immediately aliquoted into sterile microcentrifuge 
tubes following extraction and frozen at -80 °C until use in the qPCR assay.  
The qPCR assay used in this study was developed from the Aeromonas salmonicida S-
layer protein gene vapA (Gustafson, Thomas et al. 1992).  The primers and FAM-TAMRA probe 
were created with the help of Primer Express Version 3 (Applied Biosystems) and synthesized 
by Integrated DNA Technologies, Inc. (Coralville, Iowa).  Primer sequences were VapA-For 5’- 
CCC GTA AAG CAC TGT CTG TTA CC–3’ and VapA-Rev 5’-GCA ACA TCA GCA GGC 
TTC AG–3’.  The VapA probe sequence was 5’-/56-FAM/TGC CAA GCG GTG GTG CAG 
TGA /36-TAMSp/-3’. A 23bp fragment was amplified during the assay. Assays were run on an 
ABI 7500 detector, a linear regression was calculated from five DNA standards ranging from 1.5 
× 10
2
 to 1.5 × 10
6
, and all plates were run for 42 cycles.  DNA quality and quantity was 
measured using a Quawell Q3000 UV spectrophotometer (San Jose, California).  All qPCR copy 
numbers are reported per 50ng total DNA. 
Statistical Analyses 
Survival data was analyzed with a Mantel-Cox log rank test.  Parametric data were 
analyzed utilizing Chi-square analysis or one-way analysis of variance using Dunnett method 
followed by Tukey’s post-test or t test. Nonparametric data were analyzed by the Wilcoxon test 
followed by Dunn’s post-test. P values of ≤0.05 were considered statistically significant. All 
analyses were made with GraphPad Prism® 5.02 (GraphPad Software Inc., San Diego, CA), 
JMP® 10 (SAS Institute, Inc., Cary, NC), or Statistix® 8 (Analytical Software, Tallahassee, FL). 
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CHAPTER THREE: 
RESULTS 
Modified LD50  Establishment 
For fish from the USGS Tunison Laboratory of Aquatic Science, the mLD50 dose of A. 
salmonicida was 10
3
 CFU/fish. For fish from the NYSDEC Bath Hatchery, the mLD50 dose was 
10
5
 CFU/fish (Figures 2A-2C show typical gross lesions). Survival curve data is not shown.  
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Figures 2A-2C: Gross lesions associated with A. salmonicida infection 
 
A) Severe focal myofibrillar necrosis at injection site, hemorrhage at base of caudal fins and 
vent, B) abdominal swelling, hemorrhage at base of caudal fins and from vent, C) multifocal 
hepatic petechiation. 
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Feeding Trial by Direct Infection 
Two trials were performed.  For the 1
st
 direct infection feeding trial, the mLD50 dose was 
not reached and the number of positive controls was reduced to half of the originally intended 
animals (20 rather than 40 fish), so beneficial effects were likely not evident.  There was no 
significant difference in survival between the positive control group (0%) and the 0.5% and 1% 
groups (p-values 0.317 and 0.718, respectively).  However, there were significant detrimental 
differences in survival between the 2.0% group and the 0.5% and 1% groups (p-values 0.003 and 
0.028, respectively) (Figure 3), with the 2% having significantly more mortality than the other 
groups. 
Additionally, there was no significant difference in the quantity of bacteria detected from 
positive samples in any group nor was there any difference in the proportion of fish detected as 
positive on qPCR based on treatment group (Figures 4 and 5).  
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Figure 3: Trial 1 Survival 
 
LD50 dose of A. salmonicida was not reached. No significant difference was noted between the 
positive control (0%) and the 0.5% and 1% groups.  A significant detrimental effect was noted at 
2% as compared to the 0.5% and 1% groups.  
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Figure 4: Trial 1 Systemic Bacterial Levels 
 
No significant difference in A. salmonicida copy number per ng DNA within renal tissue for any 
treatment group. 
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Figure 5: Trial 1 Proportion Infected 
 
No significant difference in proportion of animals infected with A. salmonicida (positive by 
qPCR) for any treatment group. 
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For the 2
nd
 direct infection feeding trial, there was a significant difference in survival 
between the positive control and the 0.5% and 1% groups (p-values 0.006 and 0.005, 
respectively), with these treatment groups promoting significant protection.  Additionally, there 
were significant differences in survival between the 2% group and the 0.5% and 1% groups (p-
values 0.002 and 0.018, respectively) (Figure 6). 
Additionally, there was no significant difference in the quantity of bacteria detected from 
positive samples in any group; however, there was a significant difference in the proportion of 
positive samples detected per treatment group, with the 0.5% and 1% treatment groups having 
significantly less (p-values 0.023 and 0.008, respectively) infected animals compared to the 2% 
treatment group (Figures 7 and 8).  
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Figure 6: Trial 2 Survival 
 
There was a significant difference (p<0.05) in survival between the 0.5% and 1% groups as 
compared to the positive control and 2% groups, with the 0.5% and 1% having improved 
survival. 
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Figure 7: Trial 2 Systemic Bacterial Levels 
 
No significant difference in A. salmonicida copy number per ng DNA within renal tissue for any 
treatment group. 
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Figure 8: Trial 2 Proportion Infected 
 
The 0.5% and 1% treatment groups have significantly (p<0.05) less proportion of the group 
infected (positive qPCR) than the 2% groups. 
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Target Animal Safety Trial 
Length/Weight: There were no significant differences in average length or weight 
between treatment groups at the endpoint of the study (Table 1). 
Blood Smear:  Blood smears for the 0% allicin (0x) and the 2.5% allicin (5x) groups 
were evaluated.  For both groups, red blood cell morphology was normal and polychromasia was 
marked.  There was no significant difference in estimated white blood cell counts (cells/mL) for 
either group.  Both groups had a very wide range of white cell counts (0%: 1,750-15,050 
cells/mL, 2.5%: 3,150-11,900 cells/mL).  For the white blood cell differential, there was a 
statistically significant difference in the percentage of lymphocytes and monocytes (p-values 
0.02 and 0.003, respectively) with the 2.5% allicin group having a higher percentage of 
lymphocytes and a lower percentage of monocytes than the control group (Table 2).   
Non-Mammalian Serum Chemistry Panel:  There was no statistically significant 
difference between groups for the following serum chemistry parameters: sodium, potassium, 
chloride, uric acid, calcium, phosphate, total protein, glucose, AST, and lipemia.  There was a 
statistically significant increase in the GDH values between the 0% (control) allicin group and 
the 0.5% (1X), 1.5% (3X), and 2.5% (5X) allicin groups for GDH (p-values <0.0001, <0.0001, 
0.004 respectively), with all treatment groups elevated as compared to the control group  (Table 
3). 
Histology:  Gill, liver, and spleen tissue were normal from all groups. In the kidneys, 
there was a significant increase in the amount of pigment-containing macrophage centers 
between groups as the allicin dose increased (Table 4, Figures 9A and 9B). 
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Table 1: Target Animal Safety Average Lengths and Weights 
Values are presented as mean ± SD. No significant (P ≤ 0.05) differences between groups. 
Allicin Dose 0% (0x) 0.5% (1x) 1.5% (3x) 2.5% (5x) 
Weight (g) 131.8 ± 48.7 229.0 ± 20.7 225.0 ± 20.0 231.6 ± 22.6 
Length (mm) 227.6 ± 23.1 126.5 ± 38.3 121.8 ± 36.0 133.0 ± 41.9 
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Table 2: Target Animal Safety Blood Smear Analysis 
 
Values in a row with superscripts are significantly different from the control (P ≤ 0.005). 
 
 
Blood Smear 
Parameter Allicin Dose 
0x (0%) 5x (2.5%) 
RBC Morphology Normal Normal 
Polychromasia Marked Marked 
Lymphocytes (%) 78 85
 a
  
Monocytes (%) 15 8
 b
 
Avg. Estimated WBC 
Count (cells/ml) 
6,431 6,559 
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Table 3: Target Animal Safety Serum Chemistry Profiles  
Values are presented as mean ± SD.  Values in a row with different superscripts are significantly 
different (P ≤ 0.005). 
 
 Allicin Dose 
Serum Chemistry 
Parameters 
0% (0x) 0.5% (1x) 1.5% (3x) 2.5% (5x) 
Sodium (mEq/L) 160.5 ± 3.5 160.5 ± 3.2 160.8 ± 3.1 163.0 ± 3.7 
Potassium (mEq/L) 1.1 ± 0.2 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 
Chloride (mEq/L) 122 ± 3.6 125.4 ± 4.4 124.6 ± 3.1 126.2 ± 3.8 
Uric Acid (mg/dL) 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.2 
Calcium (mg/dL) 14.7 ± 1.1 15.2 ± 1.4 14.2 ± 1.3 15.5 ± 1.6 
Phosphate (mg/dL) 22.7 ± 2.3 24.0 ± 2.2 24.1 ± 2.8 24.2 ± 3.0 
Total Protein (g/dL) 4.4 ± 0.5 4.7 ± 0.6 4.5 ± 0.6 4.6 ± 0.5 
Glucose (mg/dL) 53.7 ± 33.9 42.0 ± 20.8 44.5 ± 21.7 48.4 ± 26.3 
AST (U/L) 1016.7 ± 578.4 1218.3 ± 968.0 1230.0 ± 638.2 925.7 ± 297.0 
GDH (U/L) 245.3 ± 83.4 368.8
a  
± 104.2 445.7
b 
± 169.3 328.0
c 
± 97.1 
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Table 4: Target Animal Safety Renal Pigment-Containing Macrophage Center Scoring 
 
Density of pigmentation determined by a scoring system: 1 = no pigment-containing macrophage 
centers to 5 = heavy pigment-containing macrophage centers.  Normal baseline score for control 
animals was 3, with trends indicating an increase in density as allicin dosage increased, denoting 
an inflammatory response. 
 
Renal Pigment-Containing Macrophage Center Scoring 
Allicin Treatment Group Average Score 
0x (0%) 3 
1x (0.5%) 3.1 
3x (1.5%) 3.1 
5x (2.5%) 4.2 
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Figures 9A and 9B: Target Animal Safety Renal Histopathology  
 
Scale Bar = 100 micrometers. 
A) Renal tissue from the control group (0% allicin) with a normal level of pigment-containing 
macrophage centers. Score = 3 and B) renal tissue from the 5x (2.5% allicin) showing severe 
interstitial infiltration with pigment-containing macrophage centers. Score = 5.  
 
 
 
9A 
9B 
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Feeding Trial by Waterborne Exposure 
An initial trial was performed using the initially determined modified LD50 dose of 10
3
 
CFU/fish.  After 38 days, there were no animals that showed any clinical evidence of infection 
and all animals cultured negative for the bacterium.  Since these fish were from a different 
source, a second mLD50 was performed to verify the dose, in which the dose was determined to 
be 10
5
 CFU/fish for this group of animals. 
A second waterborne exposure trial was performed, in which only two (3.1%) of the 
directly infected fish (n=64) showed clinical signs of disease and were euthanized.  These two 
animals cultured positive for A. salmonicida.  However, all remaining animals, including those 
infected by direct inoculation, survived and were culture-negative.  Quantitative PCR was not 
performed. 
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CHAPTER FOUR: 
CONCLUSIONS 
Feeding Trial by Direct Infection 
In the first trial, the mLD50 dose was not reached; therefore, a beneficial effect was 
difficult to determine.  There was no significant difference in mortality between the 0%, 0.5%, 
and 1% treatment groups, though there was a significant detrimental effect in the 2% group as 
compared to the lower allicin dose groups, indicating that there may be a negative effect at the 
highest dose group.  There was no significant difference between the quantities of A. salmonicida 
bacteria in any of the treated groups, nor was there a difference in the proportion of each 
treatment group that tested positive by qPCR. 
The second trial showed increased survivability (protection) of the 0.5% and 1% allicin 
groups as compared to the 0% and 2% allicin groups.  There was no significant difference 
between the quantity of A. salmonicida bacteria in any of the treated groups, but there was a 
difference in the proportion of fish that tested positive per group, with the 0.5% and 1% groups 
having a lower proportion of positive animals when compared to the other groups, indicating that 
the fish fed the lowest allicin doses (0.5 and 1%) may have protection against disease or are able 
to clear the disease with higher incidence.   
It is suspected that in vivo, the difference in survivability when challenged with A. 
salmonicida is based on immune up-regulation, rather than direct action on the bacteria.  This 
idea is supported by the data showing no difference in quantity of bacteria per group, but lower 
percentages of animals being affected by disease in the low-dose (0.5% and 1%) allicin groups.  
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Feeding Trial by Direct Infection: Conclusions 
1. Rainbow trout fed allicin at 0.5% and 1% had improved survivability (protection) 
when challenged with the bacterial pathogen A. salmonicida. 
2. Rainbow trout fed allicin at 2% had suspected detrimental effects denoted by 
reduced survival. 
3. Despite improved survival with low-dose allicin dosing, the quantity of systemic 
bacteria present did not differ between treatment groups, indicating a suspected 
immune-up regulation affect rather than direct activity on the bacterium. 
Target Animal Safety Trial 
Allicin supplementation did not negatively affect the average size of the animals, which 
is extremely important from a hatchery management position and in fact, other studies previously 
mentioned have shown that long-term garlic dosing can actually increase growth rate and feed 
efficiency (Fo, Han et al. 1990; Zeng, Ren et al. 1996; Jia, Hu et al. 1997; Hu 1999; Jia 1999).   
Fish from both the control and high dose groups (2.5%) exhibited normal erythrocyte 
morphology with marked polychromasia in both groups, which is a normal finding in many 
species of fish, including those of the salmonid group (Yasutake and Wales 1983).  White blood 
cell counts were not significantly different, though there was marked variability between 
individuals.  There was a significant difference in the WBC differential between the control 
group and the high dose group (2.5%), with a significantly lower percentage of monocytes in the 
high dose group.  This is suspected to be a result of monocytes being pulled out of circulation for 
redistribution into the renal tissue, as evidenced by the renal histopathology.  
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In the serum chemistry evaluations, the creatinine kinase was extremely high in all 
groups (data not shown), likely due to capture myopathy.  In an attempt to reduce capture stress 
and reduce blood chemistry alterations, small groups of fish were netted and euthanized for 
immediate processing.  The glutamate dehydrogenase (GDH) was significantly increased in all 
treatment groups from the control.  In mammals and some non-mammalian species, GDH is a 
marker of hepatocellular damage, as it is released from the hepatocyte mitochondrial membranes 
during apoptosis and is a marker of irreversible damage.  Aspartate aminotransferase (AST), a 
cytosolic enzyme, is released within hours of hepatic insult and is a more acute, sensitive 
indicator of damage in the liver, heart, skeletal muscle, and erythrocytes. In general, hepatic 
damage would be evidenced on a serum chemistry panel by an increase in AST as well as an 
increase in GDH (Boone, Meyer et al. 2005).  As the results of this study demonstrated an 
increased GDH without AST increases and liver histology was normal, it is less likely that the 
increase was due to hepatic damage. 
There are multiple alternate reasons explaining why the GDH may have been increased in 
the allicin treatment groups in the current study.  Several studies determined that allicin acts as a 
hypolipidemic drug, increasing the activity of acetyl-coenzyme A, associated with increased 
beta-oxidation (Orellana, Kawada et al. 1992; Prager-Khoutorsky, Goncharov et al. 2007), 
leading to alterations in fat and glucose metabolism.  As a result of increased activity driving the 
Krebs cycle, a higher level of GDH would be active, leading to an increase in the circulating 
levels of GDH (UCDavis 2010).  Additionally, another study found that allicin induced p53-
mediated autophagy, inhibited the viability of hepatic carcinoma lines, and induced degradation 
of mitochondria (Chu, Ho et al. 2012).  Programmed cell death may have occurred as a result of 
allicin dosing, leading to increased levels of GDH released into the circulation.  
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Histology of gill, spleen, and liver were normal for all treatment groups.  There was a 
notable, marked increase in the amount of pigment-containing macrophage centers of the kidney 
as the allicin dose increased.   Pigment-containing macrophage centers are a normal feature in 
tissues of many species of fish and represent areas of surveillance; however, the amount of 
pigment increased notably as the allicin dose increase.  This correlates to the decrease in 
circulating monocytes in the blood smear, as these cells were distributed to the renal tissue 
instead.  This may indicate an inflammatory process occurring as a direct result of allicin 
supplementation.  Inflammation is not necessarily a harmful process, but there comes a point 
where heavy inflammation starts to work against the body, causing adverse reactions.  Together 
with the previous survival data indicating that the 2% dose had detrimental survival, it is 
suspected that there is indeed an adverse reaction to the allicin at levels 2% and higher.   
Target Animal Safety: Conclusions 
1. Allicin fed at 0.5%, 1.5%, and 2.5% did not significantly alter the average length or 
weight of animals as compared to the control group. 
2. Allicin concentration (0.5%, 1.5% and 2.5%) did not affect erythrocyte or leukocyte 
morphology or concentration; however, it did alter the WBC differential, with a 
decreased percentage of monocytes in the highest dose group.  This is likely 
attributable to monocytes being removed from circulation for redistribution in the 
renal tissue. 
3. In all allicin treatment groups, glutamate dehydrogenase was elevated compared to 
the controls.  No hepatic damage was seen on histology.  GDH may have been 
increased due to the increased effect allicin has on beta-oxidation, autophagy, and 
apoptosis, leading to increased cellular metabolism and hepatocyte turnover. 
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4. In the highest allicin group (2.5%), there was a significant trend towards increasing 
pigment-containing macrophage centers within the renal interstitium, supporting 
the idea that the highest dose had a potentially negative effect (inflammation). 
Waterborne Infection Trial 
Waterborne infection trials were attempted to replicate a more natural route of infection. 
These trials were unsuccessful mainly because the LD50 dose of A. salmonicida was not 
optimized for this strain of fish.  While the direct infection trials and target animal safety trials 
were performed with fish from the same hatchery (USGS Tunison), this final trial set was 
performed with fish obtained from a different hatchery (NYSDEC Bath).  It is known that 
different populations of aquaculture fish have different genetic predispositions and resistance to 
varied pathogens; however, these genetic differences are not well recorded by hatchery 
management.  After the initial waterborne challenge, none of the shedder fish cultured positive 
for A. salmonicida, indicating that the animals cleared the infection within 14 days of exposure 
to the bacteria at a dose of 10
3
 CFU/fish.  
A new LD50 was determined with a very small cohort of fish (10 fish per group, 5 doses) 
and it was determined that the LD50 for the Bath Hatchery fish was 10
5
CFU/fish based on this 
limited study.  A second waterborne challenge was attempted, with only several of the injected 
fish showing signs of disease and culturing positive for the infection.  It is suspected that the 
LD50 was still too low as a result of the small sample size tested and this experiment was not 
optimized during this research phase. 
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Overall Conclusions 
Feeding allicin to rainbow trout appears safe and effective against A. salmonicida at 0.5%. 
This study adds to previous data indicating that garlic is a beneficial dietary supplement 
for use in rainbow trout, acting as an immunostimulant for the prevention of bacterial disease.  A 
cost-benefit analysis should be performed prior to use in a hatchery setting, though garlic may 
also improve growth rate and feed efficiency in addition to its antimicrobial functions.  It has 
been used for thousands of years to improve health and wellness to humans as well as other 
agricultural species and is an excellent environmentally-friendly natural product to consider for 
use in aquaculture.  
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